1.21 Nab-Paclitaxel in CCA, OS of PALOMA-3, Transparency, and Dr. Talal Hilal's Advice for Trainees
In this episode we question the conclusions of th…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
November 6, 20181h 12mExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode we question the conclusions of the phase II trial "Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma", review the long-term overall survival results from PALOMA-3, discuss Dr. Gyawali et al.'s paper on the need for transparency in reporting harms from cancer drugs, and interview Dr. Talal Hilal from the Scottsdale Mayo Clinic on his advice for trainees.
Nab-paclitaxel and gemcitabine: doi.org/10.1001/jamaoncol.2018.3277
Palbociclib and fulvestrant: doi.org/10.1056/NEJMoa1810527
Reporting harms: doi.org/10.1136/bmj.k4383
Topics
medicineoncologyhealthpolicy